FDA weighs black box warning for two eczema creams

Share this article:
The FDA convened an outside panel of experts this week to consider adding black box labeling to two prescription eczema creams to warn they might increase the risk of certain cancers, especially in children. The panel discussed Novartis' Elidel and Fujisawa Pharmaceuticals' Protopic after 13 reports of skin cancer and lymphoma in children and adults. Novartis said there was no evidence
Elidel causes lymphoma, noting the number of lymphomas in question "is below the number typically observed in the general population." Fujisawa said it did not believe Protopic raised the risk of skin cancer or lymphoma and that the cream "has a favorable benefit-risk ratio."
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.